Whittier Trust Co. Sells 5,805 Shares of GSK PLC Sponsored ADR $GSK

Key Points

• Whittier Trust Co. has reduced its stake in GSK PLC by 19.4%, now holding 24,049 shares worth $923,000 after selling 5,805 shares in the second quarter.
• GSK reported $1.23 earnings per share for the last quarter, exceeding the estimate of $1.12, and posted a revenue of $10.64 billion, significantly higher than the expected $7.92 billion.
• The company recently disclosed a quarterly dividend of $0.4206 per share, representing an annual yield of 3.7% with a payout ratio of 78.24%.

Whittier Trust Co. lowered its stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 19.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,049 shares of the pharmaceutical company's stock after selling 5,805 shares during the period. Whittier Trust Co.'s holdings in GSK were worth $923,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Yousif Capital Management LLC raised its holdings in shares of GSK by 7.9% in the second quarter. Yousif Capital Management LLC now owns 25,681 shares of the pharmaceutical company's stock worth $986,000 after buying an additional 1,875 shares during the last quarter. Trust Co. of Toledo NA OH raised its holdings in shares of GSK by 2.7% in the second quarter. Trust Co. of Toledo NA OH now owns 30,805 shares of the pharmaceutical company's stock worth $1,183,000 after buying an additional 797 shares during the last quarter. NBT Bank N A NY raised its holdings in shares of GSK by 3.2% in the second quarter. NBT Bank N A NY now owns 14,765 shares of the pharmaceutical company's stock worth $567,000 after buying an additional 452 shares during the last quarter. Prime Capital Investment Advisors LLC raised its holdings in shares of GSK by 9.3% in the second quarter. Prime Capital Investment Advisors LLC now owns 10,811 shares of the pharmaceutical company's stock worth $415,000 after buying an additional 924 shares during the last quarter. Finally, Valeo Financial Advisors LLC raised its holdings in shares of GSK by 3.1% in the second quarter. Valeo Financial Advisors LLC now owns 12,989 shares of the pharmaceutical company's stock worth $499,000 after buying an additional 388 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Trading Up 2.7%

Shares of GSK stock opened at $45.47 on Friday. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. The firm has a fifty day moving average price of $41.44 and a 200 day moving average price of $39.24. GSK PLC Sponsored ADR has a 1 year low of $31.72 and a 1 year high of $46.87. The stock has a market cap of $92.43 billion, a PE ratio of 21.05, a price-to-earnings-growth ratio of 1.99 and a beta of 0.53.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. During the same quarter last year, the company posted $0.43 earnings per share. The firm's revenue was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities research analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 9th. Shareholders of record on Friday, August 15th were issued a $0.4206 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a yield of 3.7%. GSK's payout ratio is presently 78.24%.

Analyst Upgrades and Downgrades

GSK has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a "hold (c)" rating on shares of GSK in a report on Wednesday, October 8th. Wall Street Zen raised shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, September 5th. Seven research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Reduce" and an average price target of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.